Shares of Inari Medical catapulted to a 12-month high Monday on a report medical devices maker Stryker is in advanced talks ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...

Stryker said its planned acquisition of Inari Medical would strengthen its position in the peripheral vascular market.

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...

Stryker said it has a definitive agreement to purchase Inari Medical for $80 per share, a big premium that values the deal at ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

As of December 3, 2024, the average one-year price target for Inari Medical is $66.15/share ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the ...

Inari is chiefly known for making peripheral vascular devices, including catheters and thrombectomy ... for treating pulmonary embolism. Rebecca Zhu, managing partner of 6 Dimensions Capital ...

Stryker announced a definitive agreement to acquire Inari Medical, Inc. for approximately $4.9 billion. Inari was founded in 201 ...